Collaborative Applications. The Authority may accept Claims from owners of Properties who wish to collaborate and establish community level measures, for example, where a street of properties would like to work together to establish a more appropriate solution for all provided the total Claim submitted does not exceed the Grant for each Property. Schedule 3 Information to be Maintained by the Authority 1 The Authority will maintain a record of:

Collaborative Applications. Applicants are permitted to submit collaborative applications, with up to all five ports as partners. Collaborative proposals must include a budget breakdown that designates the amount of funding allocated to each port and for which purposes. While the TAC expects individual proposals from each port, ports may share the writing on sections relevant to collaboration. Due to potential necessary approvals by Boards of Harbor Commissioners, the governance of shared projects may take longer to finalize than the allotted proposal development timeline. In this case, ports should provide a template for the ideal and realistic collaborative project structure and a roadmap to achieve it.

Collaborative Applications. For testing purposes two collaborative applications were developed. The first one was mimicking the industrial environment while the second was demonstrating the use of the robot outside the industry. Applications were designed in a way that the robot handled two workspaces simultaneously in parallel with the human operator. Overall four final products were produced with one set of experimental parameters.

Collaborative Applications. SUPPLIER'S SOLUTION DESCRIPTION:

Collaborative Applications. Soulsbyville School teachers are using various digital tools to enhance & further student learning, to align with the new Common Core State Standards, & to educate students about safe, effective practices when working online. (BP 6161.4 (a)) Students may be using web-based collaborative applications on school & personal devices to create & post their work to the Internet. Examples of these tools include, but are not limited to: GoogleApps, Wikispaces, Animoto, DropBox & Edmodo. Educational web-based collaborative application activities are designed to protect student privacy. Teachers who use these tools establish a semi-closed community, where participants involved in the project can work collaboratively on a project and/or post educational comments to one another. The teacher will constantly monitor student actions & work for appropriateness, but ultimately students must act responsibly. (BP 6161.4 (a)) Acceptable Use of Internet, Technology Equipment, Personal Devices & Digital Tools: Students are responsible for good behavior when using the Internet, computers, personal devices & other technology just as they are in a physical classroom. Internet, technology, & personal devices are to be used in a responsible, efficient, ethical, and legal manner for educational purposes only. (BP 6161.4 (a)) Soulsbyville School District will allow the student identified above to use the District’s computer labs, technology, & personal devices to access the Internet under the following terms & conditions:

Related to Collaborative Applications

Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.
Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.
Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

Collaborative Applications Sample Clauses

Filter & Search

Related Clauses

Parent Clauses

Related to Collaborative Applications